Drugs / Autologous HER2-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00902044 | Feb 2010 → Dec 2019 overdue | sarcoma | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous HER2-specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00902044 ↗ |
| Action | Deplete | “We now want to see if we can put a new gene in these cells that will let the T cells recognize and kill sarcoma cells.” NCT00902044 ↗ |
| Modality | Cell therapy | “we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells)” PMID 38658775 ↗ Apr 2024 |
| Route | Intravenous | “The HER2-CD28 T cells will be given into the vein through an IV line.” NCT00902044 ↗ |